Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Mayne Pharma Group Limited
  6. News
  7. Summary
    MYX   AU000000MYX0

MAYNE PHARMA GROUP LIMITED

(MYX)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Mayne Pharma : Lapse of rights and AGM Notice of Meeting clarification

10/23/2020 | 04:50am EDT

23 October 2020

Manager, Company Announcements

ASX Limited

Level 4

20 Bridge Street

SYDNEY NSW 2000

Via E-Lodgement

Dear Sir/Madam

Mayne Pharma Group Limited

Unquoted employee performance rights

We wish to advise that the following employee performance rights have lapsed in accordance with the terms of the Mayne Pharma Employee Performance Right and Option Plan.

Number

Expiry Date

Exercise Price

464,695

30 September 2024

Nil

The number of unquoted performance rights is 28,221,519.

AGM Notice of Meeting

Mayne Pharma wishes to clarify one item in relation to Resolution 4 - Issue of Shares under the Executive Share Loan Scheme (ESLS) and Performance Rights under the Employee Performance Rights and Option Plan (PROP) to the Chief Executive Officer and Managing Director. Under ASX listing rule 14.1A, the Company can confirm that if shareholders do not approve this resolution, the loan shares and performance rights would not be issued, and the Board will consider alternate arrangements to appropriately remunerate the CEO by reference to market conditions and independent advice.

This announcement is authorised by the Chairman.

Yours faithfully,

Mayne Pharma Group Limited

Laura Loftus

Company Secretary

Disclaimer

Mayne Pharma Group Limited published this content on 23 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 October 2020 08:49:07 UTC


© Publicnow 2020
All news about MAYNE PHARMA GROUP LIMITED
06/22Estelle Oral Contraceptive Now Available In the United States
AQ
06/20MAYNE PHARMA : Adds New Products to Australian Dermatology Portfolio
MT
06/20MAYNE PHARMA : Oral Contraceptive Introduced in the US; Shares Fall 3%
MT
06/20MAYNE PHARMA : 21/06/2021 Mayne Pharma Expands Australian Dermatology Portfolio
PU
06/20MAYNE PHARMA : 21/06/2021 Nextstellis® Oral Contraceptive Now Available in the U..
PU
06/20Mayne Pharma Group Limited and Mithra Pharmaceuticals, Sa Announces Availabil..
CI
05/28Mayne - Nextstellis Receives FDA Marketing Exclusivity And Phase III Data Pub..
AQ
05/27MAYNE PHARMA : Nextstellis receives fda marketing exclusivity and phase iii data..
AQ
05/26MAYNE PHARMA : 27/05/2021 Nextstellis® Receives FDA Marketing Exclusivity and Ph..
PU
05/26Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Nextstell..
CI
More news
Financials
Sales 2021 420 M 309 M 309 M
Net income 2021 -169 M -124 M -124 M
Net Debt 2021 224 M 165 M 165 M
P/E ratio 2021 -3,48x
Yield 2021 -
Capitalization 556 M 410 M 409 M
EV / Sales 2021 1,86x
EV / Sales 2022 1,58x
Nbr of Employees 967
Free-Float 81,0%
Chart MAYNE PHARMA GROUP LIMITED
Duration : Period :
Mayne Pharma Group Limited Technical Analysis Chart | MYX | AU000000MYX0 | MarketScreener
Technical analysis trends MAYNE PHARMA GROUP LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Last Close Price 0,32 AUD
Average target price 0,47 AUD
Spread / Average Target 50,1%
EPS Revisions
Managers and Directors
Scott Richards Chief Executive Officer, MD & Executive Director
Peter Paltoglou Chief Financial Officer
Roger Campbell Corbett Independent Non-Executive Chairman
Gerard G. Nahum Chief Medical Officer
Keith Moore Vice President-Research & Development
Sector and Competitors